Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody

摘要

Disclosed is the use of a therapeutically effective amount of antibody 2.13.2 in combination with a therapeutically effective amount of a taxane and a therapeutically effective amount of carboplatin in the production of a medicament for the treatment of non-small cell lung cancer in a patient in need of such treatment.